- Taunton, Jack;
- Serafimova, IM;
- Pufall, MA;
- Krishnan, S;
- Duda, K;
- Cohen, MS;
- Maglathlin, RL;
- McFarland, JM;
- Miller, RM;
- Frödin, M
Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacological potency and selectivity. Nevertheless, concerns about off-target modification motivate the development of reversible
